4//SEC Filing
CASI Pharmaceuticals, Inc. 4
Accession 0001144204-16-106812
CIK 0000895051operating
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 5:01 PM ET
Size
5.6 KB
Accession
0001144204-16-106812
Insider Transaction Report
Form 4
Ren Ken Keyong
Chief Executive Officer
Transactions
- Award
Stock Options (Right to Buy)
2016-06-02+280,701→ 280,701 totalExercise: $0.86From: 2016-06-02Exp: 2026-03-11→ Common Stock (280,701 underlying)
Footnotes (1)
- [F1]The option grant was approved by the Board of Directors on March 11, 2016, subject to stockholder approval of amendments to the 2011 Long-Term Incentive Plan (the "Amendments"). The Company's stockholders approved the Amendments on June 2, 2016.
Documents
Issuer
CASI Pharmaceuticals, Inc.
CIK 0000895051
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000895051
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 5:01 PM ET
- Size
- 5.6 KB